Emergence of high-level fluoroquinolone resistance in emm 6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 5, 2009, Pages 886-894

  Malhotra Kumar, Surbhi ^a   Van Heirstraeten, Liesbet ^a   Lammens, Christine ^a   Chapelle, Sabine ^a   Goossens, Herman ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Antibiotic resistance; Antibiotic selection; Molecular mechanisms; Mutation frequency; Respiratory fluoroquinolones

Indexed keywords

ALANINE; ASPARTIC ACID; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; LEVOFLOXACIN; MOXIFLOXACIN; PROTEIN PARC; PROTEIN PARE; SERINE; TYROSINE;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BELGIUM; CHILD; CLONAL VARIATION; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; IN VITRO SELECTION; INFANT; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; NONHUMAN; PHARYNGITIS; PREVALENCE; PULSED FIELD GEL ELECTROPHORESIS; STREPTOCOCCUS PYOGENES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; AZA COMPOUNDS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL TYPING TECHNIQUES; BELGIUM; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FLUOROQUINOLONES; HUMANS; INFANT; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; QUINOLINES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; YOUNG ADULT;

EID: 64649094268     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp057     Document Type: Article

References (21)

1. Malhotra-Kumar S, Lammens C, Chapelle S et al. Macrolideand telithromycin-resistant Streptococcus pyogenes, Belgium, 1999-2003. Emerg Infect Dis 2005; 11: 939-42.
2. Perez-Trallero E, Montes M, Orden B et al. Phenotypic and genotypic characterization of Streptococcus pyogenes isolates displaying the MLSB phenotype of macrolide resistance in Spain, 1999 to 2005. Antimicrob Agents Chemother 2007; 51: 1228-33.
3. Yan SS, Fox ML, Holland SM et al. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob Agents Chemother 2000; 44: 3196-8.
4. Malhotra-Kumar S, Lammens C, Chapelle S et al. Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes. J Antimicrob Chemother 2005; 55: 320-5.
5. Piddock LJ. Mechanisms of fluoroquinolone resistance: An update 1994-1998. Drugs 1999; 58 Suppl 2: 11-8.
6. Rozen DE, McGee L, Levin BR et al. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51: 412-6.
7. Ferech M, Coenen S, Malhotra-Kumar S et al. European Surveillance of Antimicrobial Consumption (ESAC): Outpatient quinolone use in Europe. J Antimicrob Chemother 2006; 58: 423-7.
8. Goossens H, Ferech M, Vander SR et al. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005; 365: 579-87.
9. Malhotra-Kumar S, Lammens C, Mallentjer C et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide- resistant streptococci among healthy volunteers: A randomised, double-blind, placebo-controlled study. Lancet 2007; 369: 482-90.
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
11. Figueiredo TA, Aguiar SI, Melo-Cristino J et al. DNA methylase activity as a marker for the presence of a family of phage-like elements conferring efflux-mediated macrolide resistance in streptococci. Antimicrob Agents Chemother 2006; 50: 3689-94.
12. Descheemaeker P, Chapelle S, Lammens C et al. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother 2000; 45: 167-73.
13. Billal DS, Fedorko DP, Yan SS et al. In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types. J Antimicrob Chemother 2007; 59: 28-34.
14. Stass H, Dalhoff A, Kubitza D et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-5.
15. Sierra JM, Cabeza JG, Ruiz CM et al. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin Microbiol Infect 2005; 11: 750-8.
16. Laponogov I, Veselkov DA, Sohi MK et al. Breakage-reunion domain of Streptococcus pneumoniae topoisomerase IV: Crystal structure of a Gram-positive quinolone target. PLoS ONE 2007; 2: E301.
17. Croisier D, Etienne M, Bergoin E et al. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother 2004; 48: 1699-707.
18. Orscheln RC, Johnson DR, Olson SM et al. Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics. J Infect Dis 2005; 191: 1272-9.
19. Jaggi P, Tanz RR, Beall B et al. Age influences the emm type distribution of pediatric group A streptococcal pharyngeal isolates. Pediatr Infect Dis J 2005; 24: 1089-92.
20. Ekelund K, Darenberg J, Norrby-Teglund A et al. Variations in emm type among group A streptococcal isolates causing invasive or noninvasive infections in a nationwide study. J Clin Microbiol 2005; 43: 3101-9.
21. Kaplan EL, Wotton JT, Johnson DR. Dynamic epidemiology of group A streptococcal serotypes associated with pharyngitis. Lancet 2001; 358: 1334-7.